Monday, January 29, 2018

FDA has "conducted close to 500 inspections of 503A and 503B facilities between the passage of DQSA and the end of fiscal year 2017. We have observed problematic conditions during the vast majority of these inspections and have overseen more than 150 recalls of compounded drugs and issued more than 180 warning letters."

quoted from The Honorable Scott Gottlieb, M.D., Commissioner, Food and Drug Administration, Witness Statement, found here 
Post a Comment